Open AccessHER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
Author(s) -
Joshua Peck,
Lai Wei,
Mark M. Zalupski,
Bert H. O’Neil,
Miguel Villalona Calero,
Tanios BekaiiSaab
Publication year - 2012
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000336488
Subject(s) - lapatinib , medicine , gastroenterology , oncology , epidermal growth factor receptor , population , trastuzumab , chemotherapy , cancer , breast cancer , environmental health
Biliary cancers (BCs) respond poorly to chemotherapy. Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and HER2/neu, both implicated in cholangiocarcinogenesis. This trial was designed to determine the safety and efficacy of lapatinib in BC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom